Rainer Henning, Chief Executive Officer

discovery, research and development Rainer Henning
Chief Executive Officer

Welcome by the CEO

Vaccines for many important diseases caused by viral infections remain a challenge. Despite decades of efforts progress is still urgently needed in several areas. At Viravaxx we address this need with the development of effective vaccines and precise diagnostic tools for viral infections.

In particular we focus our efforts on:

  • the Hepatitis B Virus (HBV)
  • the Human Rhinovirus (HRV)
  • the Human Immunodeficiency Virus (HIV)
  • the Respiratory Syncytial Virus (RSV)

Why did we choose these infections? Well, take Hepatitis B. There are simply no therapeutic vaccines available for the more than 250 millions of patients chronically infected which are able to lead to a functional cure. Take a look at Rhinovirus infections. They often cause exacerbations of asthma and COPD in the most vulnerable patients, pre-school children and the elderly, and yet no vaccine is even approaching the clinic. Furthermore, vaccines for HIV and respiratory syncytial virus have also remained elusive.

Viravaxx is taking up these challenges with a unique approach. We are making use of the powerful PCFiT technology (Peptide Carrier Fusion Technology) pioneered by our parent company Biomay AG for the design of allergy vaccines. We have already demonstrated its very broad utility beyond its original field for elicitation of a potent and focused immune response for viral targets.

Viravaxx designs, develops and clinically tests vaccines for HBV, HRV, HIV and RSV and will demonstrate their usefulness in prevention and therapy of these viral diseases. This will be complemented with unique micro-arrayed diagnostic tools, which allow the in-depth analysis of the immune response to viral infections down to the epitope level.

We are very excited at Viravaxx to explore these novel and challenging avenues to provide protection and cure for scores of patients worldwide.